Territorial Availability: Available through Bertin Technologies only in France
- Product Overview:
GPR17 is a G protein-coupled receptor that has been identified as a dualistic receptor recognizing signals from two unrelated chemical families: nucleotides and cysteinyl leukotrienes (CysLTs).{16467} The deorphanization of GPR17 supports the suggested crosstalk between nucleotides and CysLTs during inflammation and injury. mRNA transcripts encoding this transmembrane receptor are most strongly expressed in the brain, kidney, and heart. Upon ischemic injury, GPR17 is upregulated in these tissues and its inhibition has been shown to decrease ischemic damage.This finding suggests GPR17 as a pharmacological target of ischemic injury.{16467} Cayman’s peptide affinity-purified polyclonal antibody recognizes the C-terminal region of human GPR17. This protein exists in two isoforms, differing by 28 amino acids at the receptor N-terminus. The longer form of the protein consists of 367 amino acids with a calculated molecular weight of 41 kDa. The human and rat proteins share 89% amino acid identity.{16467} Post-translational modifications may explain the observed SDS-PAGE gel-migration to 57 kDa on immunoblot.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.